Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Cancers|April 29, 2020
Effect of Transgene Location, Transcriptional Control Elements and Transgene Features in Armed Oncolytic AdenovirusesMartí Farrera-Sal, Cristina Fillat, Ramon AlemanyClinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2021
Evolving Status of Clinical Immunotherapy with Oncolytic AdenovirusMartí Farrera-Sal, Laura Moya-Borrego, Miriam Bazan-Peregrino, et al.Journal for Immunotherapy of Cancer|January 27, 2019
Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engagerJana de Sostoa, Carlos Alberto Fajardo, Rafael Moreno, et al.Molecular Therapy Oncolytics|August 11, 2021
Hyaluronidase expression within tumors increases virotherapy efficacy and T cell accumulationMartí Farrera-Sal, Rafael Moreno, Ana Mato-Berciano, et al.International Journal of Molecular Sciences|July 26, 2020
Arming Oncolytic Adenoviruses: Effect of Insertion Site and Splice Acceptor on Transgene Expression and Viral FitnessMartí Farrera-Sal, Jana de Sostoa, Estela Nuñez-Manchón, et al.NAR Cancer|July 28, 2021
Transgene codon usage drives viral fitness and therapeutic efficacy in oncolytic adenovirusesEstela Núñez-Manchón, Martí Farrera-Sal, Marc Otero-Mateo, et al.Pharmaceutics|July 29, 2023
cCPE Fusion Proteins as Molecular Probes to Detect Claudins and Tight Junction Dysregulation in Gastrointestinal Cell Lines, Tissue Explants and Patient-Derived OrganoidsAyk Waldow, Laura-Sophie Beier, Janine Arndt, et al.Iscience|November 10, 2025
Multi-parametric profiling of IL-7-augmented GD2.CART products in a phase 1 clinical trialSarah Schulenberg, Martí Farrera-Sal, Michelle Loeser, et al.Molecular Therapy. Methods & Clinical Development|September 16, 2025
Effects of CRISPR-Cas9-mediated <i>FOXP3</i> knockout on CAR T cell potencyLena Peter, Martí Farrera-Sal, Ferhat Ali Yaman, et al.Journal of Controlled Release : Official Journal of the Controlled Release Society|March 6, 2021
Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11Ana Mato-Berciano, Sara Morgado, María V Maliandi, et al.Pageof 2